NDC 70518-4571-01 - buprenorphine hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70518-4571
- Requested NDC
- 70518-4571-01
- Package NDCs from labels
- 70518-4571-1, 70518-4571-0, 70518-4571-2, 70518-4571-01
- Manufacturer
- REMEDYREPACK INC.
- Effective date
- 2026-07-07
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| buprenorphine hydrochloride - REMEDYREPACK INC. | REMEDYREPACK INC. | 2026-07-07 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70518-4571-0 | buprenorphine hydrochloride | 30 in 1 BOX | TABLET | 30 | 1 | |
| 70518-4571-1 | buprenorphine hydrochloride | 1 in 1 POUCH | TABLET | 1 | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ACD-A | ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A | Fenwal, Inc. | 22805f0d-ba58-41ea-b245-19980abcda22 | 2022-02-11 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | d763511e-f1a7-4014-94b9-f7ad8f023ff4 | 2021-12-02 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | cf9f43a0-c750-4cf0-ac49-176ab2105aab | 2021-12-02 | XF417D3PSL B22547B95K | |
| InterSol | PLATELET ADDITIVE 3 | Fenwal, Inc. | e4f06c0b-7cb1-49c9-97a4-2cfc21298495 | 2021-11-16 | Warnings, Adverse reactions | B22547B95K |
| Solucion InterSol | SOLUCION ADITIVA PARA PLAQUETAS 3 | Fenwal, Inc. | d5eaf5f4-67d3-4475-af9a-f5b0f882f5d1 | 2021-10-04 | Warnings, Adverse reactions | B22547B95K |
| InterSol | PLATELET ADDITIVE 3 | Fenwal, Inc. | a00c4a93-cde2-4753-81f7-0d6fee9fb690 | 2020-10-20 | Warnings, Adverse reactions | B22547B95K |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | ee831456-5962-4d5e-ad0c-69ab85860453 | 2020-06-03 | XF417D3PSL B22547B95K | |
| Renacidin | CITRIC ACID, GLUCONOLACTONE AND MAGNESIUM CARBONATE | United-Guardian, Inc. | 13a9bbba-db21-4cba-991c-5d8afaf2ed74 | 2019-12-17 | Warnings, Adverse reactions | XF417D3PSL |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 14445dfd-6041-40cd-a043-3f4da6bcb9c1 | 2019-11-18 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 2557199a-5f60-49d8-b093-1e0700211243 | 2019-11-18 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 794f724c-87f0-49c1-9b26-c9e491978313 | 2019-11-18 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 5c7d3287-883a-459b-9214-074a583c8a59 | 2019-11-18 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 448a1dc5-7a98-4b2f-82af-4b92de05cfc3 | 2019-11-18 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 051f7347-5a76-4664-8fe2-e61b3dfcb0e4 | 2014-08-27 | XF417D3PSL B22547B95K |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.